IMBiotechologies Ltd. (IMB)
IMB is a Med Tech company with near term revenue opportunity for the first FDA cleared biodegradable embolic to treat vascularized tumors.
IMB is a privately held Canadian biotechnology company focused on commercializing medical device products in the area of embolotherapy. IMB’s lead product is OCL 500, the first biodegradable embolic particle cleared for marketing by the US FDA. Embolic agents are used to treat malignant (e.g. liver cancer) and non-malignant (e.g. uterine fibroids) solid hypervascularized tumors, and hyperplastic tissues (e.g. benign prostatic hyperplasia; BPH).